Cargando…

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015

This cross-sectional study examines the frequency of disagreements within the US Food and Drug Administration (FDA) regarding approval of novel therapeutic agents.

Detalles Bibliográficos
Autores principales:	MacGregor, Andrea, Zhang, Audrey D., Wallach, Joshua D., Ross, Joseph S., Herder, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382003/ https://www.ncbi.nlm.nih.gov/pubmed/32706379 http://dx.doi.org/10.1001/jamanetworkopen.2020.9498

Ejemplares similares

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018
por: Wallach, Joshua D., et al.
Publicado: (2021)

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
por: Wallach, Joshua D., et al.
Publicado: (2021)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Agreements and disagreements regarding “shaken baby syndrome”
por: Lynøe, Niels, et al.
Publicado: (2022)

Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
por: Downing, Nicholas S., et al.
Publicado: (2016)

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
por: Zhang, Audrey D., et al.
Publicado: (2020)

Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020
por: Zhang, Audrey D., et al.
Publicado: (2021)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

The Romance of Learning from Disagreement. The Effect of Cohesiveness and Disagreement on Knowledge Sharing Behavior and Individual Performance Within Teams
por: van Woerkom, Marianne, et al.
Publicado: (2009)

Deep Disagreement (Part 2): Epistemology of Deep Disagreement
por: Ranalli, Chris, et al.
Publicado: (2022)

Deep Disagreement (Part 1): Theories of Deep Disagreement
por: Ranalli, Chris, et al.
Publicado: (2022)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Overprescribing of Opioids to Adults by Dentists in the U.S., 2011–2015
por: Suda, Katie J., et al.
Publicado: (2020)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Disagreement, Certainties, Relativism
por: Kusch, Martin
Publicado: (2018)

Rationally irresolvable disagreement
por: Melchior, Guido
Publicado: (2023)

Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)
por: Eadie, Ashley L., et al.
Publicado: (2021)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
por: DiStefano, Michael J., et al.
Publicado: (2022)

Reasons for disagreement regarding illnesses between older patients with multimorbidity and their GPs – a qualitative study
por: Hansen, Heike, et al.
Publicado: (2015)

The Hospital Saturday Fund Disagreement
Publicado: (1891)

Disagreement, Unenforceability, and Harm Reduction
por: Weinstock, Daniel M.
Publicado: (2020)

The Precautionary Principle and Expert Disagreement
por: Elkin, Lee
Publicado: (2021)

Investigating disagreement in the scientific literature
por: Lamers, Wout S, et al.
Publicado: (2021)

Skeptical Arguments and Deep Disagreement
por: Melchior, Guido
Publicado: (2021)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Socioeconomic, Geospatial, and Geopolitical Disparities in Access to Health Care in the US 2011–2015
por: Towne, Samuel D.
Publicado: (2017)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
por: Rathi, Vinay K., et al.
Publicado: (2020)

Solar neutrino models: is there disagreement with experiment?
por: Morrison, Douglas Robert Ogston
Publicado: (1991)

Disagreement on expectations: firms versus consumers
por: Claveria, Oscar
Publicado: (2022)

Scaling and Disagreements: Bias, Noise, and Ambiguity
por: Uma, Alexandra, et al.
Publicado: (2022)

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development
por: Faucette, Stephanie, et al.
Publicado: (2017)

US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera M., et al.
Publicado: (2023)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lf18urg7q6fll6492udsv9sgaf